<DOC>
<DOCNO>EP-0652887</DOCNO> 
<TEXT>
<INVENTION-TITLE>
NEW DERIVATIVES OF NEURAMINIC ACID.
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K3170	A61K3170	A61K317012	A61K317012	A61K3800	A61K3800	A61P900	A61P910	A61P2500	A61P2500	A61P2528	C07H700	C07H7027	C07H1300	C07H1304	C07H1306	C07H1308	C07H1310	C07H1500	C07H1504	C07K500	C07K506	C07K900	C07K900	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61K	A61K	A61K	A61K	A61P	A61P	A61P	A61P	A61P	C07H	C07H	C07H	C07H	C07H	C07H	C07H	C07H	C07H	C07K	C07K	C07K	C07K	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K31	A61K31	A61K31	A61K38	A61K38	A61P9	A61P9	A61P25	A61P25	A61P25	C07H7	C07H7	C07H13	C07H13	C07H13	C07H13	C07H13	C07H15	C07H15	C07K5	C07K5	C07K9	C07K9	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Provided are new derivatives of neuraminic acid of formula (I), where Ac represents an acyl residue of an aliphatic, araliphatic, aromatic, alicyclic, or heterocyclic carboxylic acid, including carboxylic amides, their 2-hydrocarbyl-glycosides, and their peracylated derivatives at the hydroxy groups of both these series of amides. These compounds are therapeutically useful in providing a protective effect against the neurotoxicity induced by excitatory amino acids, and can therefore be used in therapies of the central nervous system following cerebral degenerations or lesions, metabolic dysfunctions, aging, and toxic-infective and chronic neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's diseases.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
FIDIA SPA
</APPLICANT-NAME>
<APPLICANT-NAME>
FIDIA S.P.A.
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
KIRSCHNER GUNTER
</INVENTOR-NAME>
<INVENTOR-NAME>
MANEV HARI
</INVENTOR-NAME>
<INVENTOR-NAME>
ROMEO AURELIO
</INVENTOR-NAME>
<INVENTOR-NAME>
TOFFANO GINO
</INVENTOR-NAME>
<INVENTOR-NAME>
TRIMARCO MARTINO
</INVENTOR-NAME>
<INVENTOR-NAME>
KIRSCHNER, GUNTER
</INVENTOR-NAME>
<INVENTOR-NAME>
MANEV, HARI
</INVENTOR-NAME>
<INVENTOR-NAME>
ROMEO, AURELIO
</INVENTOR-NAME>
<INVENTOR-NAME>
TOFFANO, GINO
</INVENTOR-NAME>
<INVENTOR-NAME>
TRIMARCO, MARTINO
</INVENTOR-NAME>
</INVENTORS>
<DESCRIPTION>
 NEW DERIVATIVES OF NEURAMINIC ACIDBACKGROUND OF THE INVENTION Field of the InventionThe present invention relates to new derivatives of neuraminic acid, especially carboxylic amides of the following formula,where Ac represents an acyl residue of a carboxylic acid of the aliphatic, araliphatic, aromatic, alicyclic or heterocyclic series, comprising the carboxylic amides, their 2-hydrocarbyl-glycosides, and their peracylated derivatives at the hydroxy groups of both these series of amides.These compounds have interesting pharmacological properties, especially a protective effect against the neurotoxicity induced by excitatory amino acids of the of glutamic acid type, and can therefore be used in therapies of the central nervous system, such as those following cerebral degenerations or lesions, e.g., ischemia, hypoxia, epilepsy, trauma or compressions, metabolic dysfunctions, aging, toxic-infective and 

chronic neurodegenerative diseases, like Alzheimer's, Parkinson's, and Huntington's diseases.The carboxylic amides and their derivatives of formula I according the present invention are new.Description of Related ArtIn the literature, there is a description of the non-substituted amide of N-acetyl-neuraminic acid, prepared as an intermediate in the synthesis of tetrazolyl-2-decarboxy-N-acetyl-neuraminic acid (see Ann. 1986, 2104-11) .In an article published in Hoppe Seyler's Physiol. Chemie, 1983, 364 (109) 1411-17, there is a description of the amides obtainable through the reaction of the benzylketoside of N-acetyl-neuraminic acid with L-glycine, L-glutamic acid, and L-phenylalanine, followed by the elimination of the benzyl group through catalytic hydrogenation; no pharmacological action is described for these derivatives.SUMMARY OF THE INVENTIONIn addition to providing new derivatives of neuraminic acid, the present invention also provides pharmacological preparations containing the aforesaid derivatives for therapeutic use. A third object of the present invention concerns the therapeutic use of these preparations.A final object of the present invention concerns procedures for the production of these new derivatives.Further scope of the applicability of the present invention will become apparent from the detailed description provided below. However, it should be understood that the detailed description and specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and 

scope of the
</DESCRIPTION>
<CLAIMS>
IN THE CLAIMS;
1. A compound selected from the group consisting of a carboxylic amide of a compound of formula I:

 wherein Ac represents an acyl residue of an aliphatic, araliphatic, aromatic, alicyclic or heterocyclic carboxylic acid, a 2-hydrocarbyl-glycoside of said amide, a peracylated derivative of said amide, a basic addition salt of one of the foregoing compounds, and an acidic addition salt of one of the foregoing compounds having an acidic or basic function. 2. A carboxylic amide according to claim 1, wherein position 2 is in the α configuration. 3. A carboxylic amide according to claim 1, wherein position 2 is in the β configuration. 4. A carboxylic amide according to any one of claims 1-3, wherein said acyl group Ac has at least 4 and not more than 24 carbon atoms, derived from a substituted or non-substituted acid, one to three substituents selected from the group consisting of a halogen atom, a free, esterified, or etherified hydroxylic or mercapto group, a free or esterified carboxylic or sulfonic group, a free or esterified carboxylic or sulfonic group transformed into an amide, a free or amino group-substituted hydrocarbylic group, and a hydrocarbylic group interrupted by an -SO-, -SO2-, or phenylene group. 5. A carboxylic amide according to claim 4, wherein said halogen atom is a member selected from the group consisting of fluorine, chlorine and bromine. 



 6. A carboxylic amide according to claim 4, wherein said esterified hydroxylic or mercapto group is derived from an aliphatic or aromatic acid with not more than 8 carbon atoms. 7. A carboxylic amide according to claim 4, wherein said etherified hydroxy or mercapto group, or said esterified carboxylic or sulfonic group, is derived from an aliphatic alcohol with not more than 8 carbon atoms, or from an araliphatic alcohol with only one benzene ring and an alkylene of 1 or 2 carbon atoms. 8. A carboxylic amide according to claim 4, wherein said hydrocarbylic group which substitutes said amino group is an alkyl with at least 8 carbon atoms or an aralkyl with one benzene ring and an alkylene of 1 or 2 carbon atoms. 9. A carboxylic amide according to claim 4, wherein said acyl group Ac is saturated. 10. A carboxylic amide according to any one of claims 1-9, wherein said acyl group Ac is unsaturated and contains only one double bond. 11. A carboxylic amide according to any one of claims 1-4, wherein said acyl group Ac is derived from an acid selected from the group consisting of butyric, valeric, caproic, enantic, caprilic, pelargonic, capric, undecilic, di-tert-butyl-acetic, 2-propyl-valeric, lauric, tridecilic, myristic, pentadecilic, palmitic, margaric, stearic, arachic, behenic and lignoceric acid. 12. A carboxylic amide according to any one of claims 1-4, wherein said acyl group Ac is derived from an acid selected from the group consisting of levulinic, succinic, valine, leucine, phenylalanine, tryptophan, a- aminobutyric, β-aminobutyric, methionine, lysine, aspartic, glutamic, proline, and hydroxyproline. 


 13. A carboxylic amide according to any one of claims 1-4, wherein said acyl group Ac is derived from mono- or dichloro-butyric acid, trichloro-butyric acid or tribromo-butyric acid. 14. A carboxylic amide according to any one of claims 1-4, wherein said acyl group Ac is derived from a natural or synthetic peptide having not more than 12 carbon atoms. 15. A carboxylic amide according to any one of claims 1-4, wherein said acyl group Ac is derived from a peptide contained in the thymus gland. 16. A carboxylic amide according to any one of claims 1-4, wherein said acyl group Ac is derived from phenylacetic, cinnamic, phenylpropionic or atropic acid. 17. A carboxylic amide according to any one of claims 1-4, wherein said acyl group Ac is derived from benzoic acid and its methylated homologues, salicylic acid, anthranilic acid, trimethoxybenzoic acid, phthalic acid, terephthalic acid, diphenyl-o,o' -dicarbonic acid, chloro-benzoic acid, vanillic acid, veriatric acid, or piperonilic acid. 18. A carboxylic amide according to any one of claims 1-4, wherein said acyl group Ac is derived from a heterocyclic acid selected from the group consisting of nicotinic, isonicotinic, cinconninic, lysergic, isolysergic, dihydrolysergic, 2-bromo-lysergic, 2-bromo-dihydrolysergic, 1-methyl-lysergic, 1-methyl-dihydro-lysergic, 1- methyl-2-bromo lysergic, and teophyllinacetic acid. 19. A carboxylic amide according to any one of claims 1-18, wherein the amido group is a non- substituted amide, -CONH
2
, or is derived from a primary or secondary aliphatic, aromatic, araliphatic, alicyclic or heterocyclic amine having not more than 24 carbon atoms. 


 20. A carboxylic amide according to any one of claims 1-19, wherein said hydrocarbylic residue is substituted with one to three groups selected from the group consisting of a free, esterified or etherified hydroxylic or mercapto group, a halogen atom, a free, esterified, or amide-modified carboxylic or sulfonic group, a free amino group, and a hydrocarbyl-substituted amino group wherein said hydrocarbyl group is blocked with an -SO- or -S0
2
- group. 21. A carboxylic amide according to claim 20, wherein said esterified hydroxy or mercapto group is derived from an aliphatic or aromatic acid having not more than 8 carbon atoms. 22. A carboxylic amide according to claim 20, wherein said esterified hydroxy or mercapto group, or said esterified carboxylic or sulfonic group, is derived from an aliphatic alcohol having not more than 8 carbon atoms, or from an araliphatic alcohol having only one benzene ring and an alkylene of 1 or 2 carbon atoms. 23. A carboxylic amide according to claim 20, wherein said hydrocarbylic group substituting said amino group is an alkyl having not more than 8 carbon atoms, or an aralkyl with only one benzene ring and an alkylene of 1 or 2 carbon atoms. 24. A carboxylic amide according to claim 19, wherein said amino group is derived from an alkyl- or dialkylamine having between 1 and 12 carbon atoms. 25. A carboxylic amide according to claim 19, wherein said amino group is derived from an alkylenamine having between 3 and 6 carbon atoms constituting the ring. 26. A carboxylic amide according to claim 19, wherein the amidic group derives from methylamine, ethylamine, propylamine, hexylamine, diethylamine, dimethylamine, diisopropylamine, dihexylamine pyrrolidine, pyperidine, or azepine. 


 27. A carboxylic amide according to claim 19, wherein the amidic group derives from an aliphatic diamine. 28. A carboxylic amide according to claim 27, wherein said diamine is selected from the group consisting of ethylenediamine, trimethylenediamine, tetramethylenediamine , pentamethylenediamine , hexamethylenediamine, piperazine, and its N-alkyl or C-alkyl derivatives having a Cl-4 alkyl. 29. A carboxylic amide according to claim 19, wherein the amidic group is derived from aminoethanol, aminopropanol, mercaptoethylamine, morpholine, tiomorpholine, and a Cl-4 alkylated derivative thereof. 30. A carboxylic amide according to claim 19, wherein the amidic group is derived from an amino acid selected from the group consisting of valine, leucine, phenylalanine, tryptophan, o;-aminobutyric acid, β-aminobutyric acid, methionine, lysine, aspartic acid, glutamic acid, proline, and hydroxyproline. 31. A carboxylic amide according to claim 19, wherein the amidic group is derived from a natural or synthetic peptide having not more than 12 carbon atoms. 32. A carboxylic amide according to claim 19, wherein the amidic group is derived from a peptide contained in the thymus gland. 33. A carboxylic amide according to claim 19, wherein the amidic group is derived from an amine selected from the group consisting of phosphatidyl- ethanolamine, phosphatidylserine, sphingosine, dihydrosphingosine, psychosine, dihydropsychosine, phosphorylcholine-sphingosine, phosphorylcholine- dihydrosphingosine, and phytosphingosine. 3 . A carboxylic amide according to claim 19, wherein the amidic group is derived from an aromatic amine having only one non-substituted aromatic ring, or an aromatic amine substituted with one to three functional groups selected from the group consisting of 


a halogen, a hydroxylic or methoxylic group, a carboxylic or sulfonic group, and a Cl-4 lower aliphatic hydrocarbylic group. 35. A carboxylic amide according to claim 19, wherein the amidic group is derived from a heterocyclic amine selected from the group consisting of a pyrimidine base, a purine, ephedrine, tyramine, and adrenaline. 36. A carboxylic amide according to any one of claims 1-35, wherein the 2-hydrocarbyl-glycoside is derived from an aliphatic alcohol having not more than 12 carbon atoms. 37. A carboxylic amide according to any one of claims 1-35, wherein the 2-hydrocarbyl-glycoside is derived from an araliphatic alcohol having only one non- substituted benzene ring, or a benzene ring substituted with 1 - 3 lower Cl-4 alkyl groups, and having not more than 4 carbon atoms in the aliphatic chain. 38. A carboxylic amide according to any one of claims 1-35, wherein the 2-hydrocarbyl-glycoside is derived from an alicyclic alcohol or an aliphatic-alicyclic alcohol having only one cycloaliphatic ring and not more than 14 carbon atoms. 39. A carboxylic amide according to any one of claims 1-35, wherein the 2-hydrocarbyl-glycoside is derived from a heterocyclic alcohol having not more than 12 carbon atoms, and only one heterocyclic ring containing 1 or 2 heteroatoms selected from the group consisting of -NH-, -0- , and -S- . 40. A carboxylic amide according to any one of claims 1-35, wherein the 2-hydrocarbyl-glycoside is derived from a corticosteroid steroid alcohol. 41. A carboxylic amide according to any one of claims 1-40, wherein in the peracylated derivatives, the acyl groups are derived from aliphatic acids having not more than 10 carbon atoms. 42. A carboxylic amide according to any one of claims 1-41, wherein in the peracylated derivatives, the 



acyl groups are derived from aromatic acids having only one benzene ring. 43. The /3-2-O-ethylglycoside of N-palmitoyl- neuraminic acid. 44. The 0-2-O-ethylglycoside dimethylamide of N-palmitoyl-neuraminic acid. 45. The j8-2-0-ethylglycoside of N-acetylneuraminic acid amide with arginine. 46. The G.-2-O-ethylglycoside of N-acetylneuraminic acid amide with arginine. 47. The /3-2-0-ethylglycoside of N-palmitoyl- neuraminic acid amide with L-alanine-D-isoglutamine. 48. The β-2-O-ethylglycoside of N-acetylneuraminic acid amide with L-alanine-D-isoglutamine. 49. The α.-2-O-ethylglycoside of N-acetylneuraminic acid amide with L-alanine-D-isoglutamine. 50. The α.-2-O-ethylglycoside dimethylamino- propylamide of N-acetylneuraminic acid. 51. The α-2-O-ethylglycoside butylamide of N-acetyl-neuraminic acid. 52. The /3-2-O-ethylglycoside dimethylamide of N-acetyl-neuraminic acid. 53. The jS-2-O-ethylglycoside dimethylamino- propylamide of N-acetylneuraminic acid. 54. The jS-2-O-ethylglycoside benzylamide of N-acetylneuraminic acid. 55. The -2-O-ethylglycoside butylamide of N-acetylneuraminic acid. 56. The butylamide of N-acetylneuraminic acid. 57. A compound selected from the group consisting of a carboxylic ester of a compound of the following formula:

 wherein Ac represents any acyl residue of an aliphatic, araliphatic, aromatic, alicyclic, or heterocyclic carboxylic acid, a 2-hydrocarbyl-glycoside thereof, a peracylated derivative thereof, and a basic or acidic addition salt thereof having an acidic or basic function. 58. A process for preparing a carboxylic amide of N-acylneuraminic acid of claim 1, comprising introducing, in a stepwise manner, the amide function, the 2-glycosidic group, and the acyl groups into the hydroxy groups, and forming their salts. 59. The process according to claim 58, wherein the carboxylic group of an N-acylneuraminic acid or of one its 2-hydrocarbyl glycosidic derivatives is transformed into an amidic group, and optionally, wherein the obtained compound is converted into a peracylated derivative at the hydroxy groups therein. 60. The process according to claim 58, wherein the carboxylic group of said neuraminic acid is converted into the desired amide, and eventually the 2-hydroxy group in its hydrocarbyl derivative in any order, and the free amino group is acylated with the desired acid, and optionally, the free hydroxy groups are peracylated. 61. The process according to claim 60, wherein the peracylation is performed in any step of the process. 62. A process for preparing said ester or derivative thereof according to claim 57, comprising introducing, in a stepwise manner, the ester function and eventually the 2-glycosidic group into an N-acyl-neuraminic acid, and the acyl groups into the hydroxy groups, and eventually forming salts of said amide. 63. The process according to any one of claims 58 or 62, further comprising starting from an intermediate compound and performing the remaining steps, or stopping 


the process at any step, or preparing intermediate compounds m situ. 64. Use of the compound according to claim 1 for therapeutic purposes. 65. Use of a compound according to claim 1 for the therapy of diseases and disorders of the central nervous system. 66. The use according to claim 65, wherein said diseases and disorders of the central nervous system are selected from the group consisting of ischemia, hypoxia, epilepsy, trauma and compressions, metabolic dysfunctions, aging, and toxic-infective and neurodegenerative diseases. 67. A pharmaceutical composition, comprising a compound according to claim 1 as active ingredient, and a pharmaceutically accetable carrier. 

</CLAIMS>
</TEXT>
</DOC>
